GCP
GTHX

GSA Capital Partners’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

GSA Capital Partners’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-28,729
Closed -$66K – 2106
2024
Q2 		$66K Buy
28,729
+17,955
+167% +$68.6K ﹤0.01% 1556
2024
Q1 		$47K Sell
10,774
-15,243
-59% -$53.1K ﹤0.01% 1536
2023
Q4 		$79K Buy
26,017
+6,651
+34% +$12.5K 0.01% 1409
2023
Q3 		$28K Sell
19,366
-246,651
-93% -$477K ﹤0.01% 1433
2023
Q2 		$662K Buy
+266,017
New +$727K 0.07% 566
2022
Q4 		– Sell
-11,042
Closed -$138K – 1983
2022
Q3 		$138K Sell
11,042
-192,503
-95% -$2.2M 0.02% 1312
2022
Q2 		$1.01M Buy
+203,545
New +$1.13M 0.15% 142
2020
Q4 		– Sell
-35,742
Closed -$413K – 1680
2020
Q3 		$413K Buy
+35,742
New +$590K 0.07% 513
2020
Q2 		– Sell
-25,428
Closed -$280K – 1208
2020
Q1 		$280K Buy
+25,428
New +$475K 0.07% 530

GSA Capital Partners's GTHX Position: Q3 2024 in Review

GSA Capital Partners sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q3 2024, closing a stake of 28,729 shares — an estimated $66K sold.

GSA Capital Partners first reported a position in GTHX in Q1 2020 and held it in 9 quarters. The position peaked at $1.01M in Q2 2022. 0 funds tracked by Wall St. Rank hold GTHX as of Q3 2024.

  • GSA Capital Partners reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • GSA Capital Partners sold 28,729 G1 Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $66K.
  • GSA Capital Partners first reported a position in G1 Therapeutics, Inc. Common Stock in Q1 2020 and held it in 9 quarters.
  • GSA Capital Partners's G1 Therapeutics, Inc. Common Stock position peaked at $1.01M in Q2 2022.
  • 0 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q3 2024.

Based on GSA Capital Partners's 13F filing for Q3 2024, filed 5 Nov 2024.